Reporter brief
Fisetin senolytic showed safety signals in Phase I/II osteoarthritis trial; efficacy unclear
What happened
This Phase I/II randomized, double-blind, placebo-controlled trial tested the senolytic drug fisetin in patients with mild to moderate osteoarthritis. The abstract reports testing for safety and efficacy, but does not present actual efficacy results or sample size details.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Not recorded.
- Design
- Rct
- Sample
- —
- Journal
- Steadman Philippon Research Institute
- Published
- Sep 19, 2024
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.